Great Valley Advisor Group Inc. Sells 233 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Great Valley Advisor Group Inc. lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 35.6% during the 2nd quarter, HoldingsChannel reports. The firm owned 421 shares of the biopharmaceutical company’s stock after selling 233 shares during the period. Great Valley Advisor Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $443,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. West Paces Advisors Inc. increased its stake in shares of Regeneron Pharmaceuticals by 575.0% during the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 23 shares in the last quarter. Crewe Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter worth about $28,000. MCF Advisors LLC grew its stake in Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 12 shares in the last quarter. Lynx Investment Advisory bought a new position in Regeneron Pharmaceuticals in the 2nd quarter worth about $33,000. Finally, Criterion Capital Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $37,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 22,830 shares of the stock in a transaction on Friday, May 17th. The stock was sold at an average price of $979.23, for a total value of $22,355,820.90. Following the sale, the chief executive officer now owns 466,877 shares in the company, valued at $457,179,964.71. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 22,830 shares of the firm’s stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $979.23, for a total value of $22,355,820.90. Following the completion of the sale, the chief executive officer now owns 466,877 shares of the company’s stock, valued at $457,179,964.71. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Leonard S. Schleifer sold 9,064 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $1,015.43, for a total value of $9,203,857.52. Following the transaction, the chief executive officer now owns 55,134 shares of the company’s stock, valued at $55,984,717.62. The disclosure for this sale can be found here. Insiders sold a total of 40,561 shares of company stock worth $40,585,963 over the last 90 days. Corporate insiders own 7.48% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on REGN shares. Barclays lifted their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. TD Cowen upped their target price on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Canaccord Genuity Group reiterated a “buy” rating and set a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. Piper Sandler upped their price objective on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,166.00 and gave the stock an “overweight” rating in a research report on Friday, July 19th. Finally, Truist Financial reiterated a “buy” rating and issued a $1,200.00 price target (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 2nd. One analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $1,097.05.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $1,156.86 on Thursday. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10. The business has a 50-day simple moving average of $1,063.88 and a 200 day simple moving average of $992.29. Regeneron Pharmaceuticals, Inc. has a 52 week low of $769.19 and a 52 week high of $1,161.21. The stock has a market cap of $127.47 billion, a price-to-earnings ratio of 34.18, a PEG ratio of 2.99 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The firm had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $8.79 EPS. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.